Related Experiment Video

Updated: Jun 21, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Inhibition of PI3K and MEK: it is all about combinations and biomarkers

Brent N Rexer1, Ritwik Ghosh, Carlos L Arteaga

  • 1Department of Medicine, Breast Cancer Research Program, Vanderbilt-Ingram Comprehensive Cancer Center; Vanderbilt University School of Medicine, Nashville, Tennessee 37232-6307, USA.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|July 9, 2009
PubMed

Insights

A MEK inhibitor showed promise against basal-like breast cancer. Combining MEK and PI3K inhibitors may overcome resistance mechanisms and improve antitumor activity in these cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Basal-like breast cancer is an aggressive subtype with limited targeted therapy options.
  • MAP/ERK kinase (MEK) signaling is implicated in breast cancer proliferation.
  • Understanding resistance mechanisms is crucial for developing effective treatments.

Purpose of the Study:

  • To evaluate the efficacy of a MEK inhibitor in basal-like breast cancer models.
  • To investigate the mechanisms of resistance to MEK inhibition.
  • To identify potential combination therapies to overcome resistance.

Main Methods:

  • Treatment of human basal-like breast cancer cells with a MEK inhibitor.
  • Analysis of signaling pathway activation, including PI3K/AKT and PTEN.
  • Assessment of antitumor activity in vitro and potentially in vivo.

Main Results:

  • The MEK inhibitor demonstrated effectiveness against basal-like breast cancer cells.
  • Feedback upregulation of phosphatidylinositol-3 kinase (PI3K)/AKT was observed upon MEK inhibition.
  • Loss of the phosphatase PTEN contributed to resistance.
  • Antitumor activity was limited by these resistance mechanisms.

Conclusions:

  • MEK inhibitors show potential as a therapeutic strategy for basal-like breast cancer.
  • Combination therapy with PI3K inhibitors is warranted to overcome resistance.
  • Targeting both MEK and PI3K pathways may enhance treatment efficacy in basal-like breast cancers.

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...